TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Simcere Pharmaceutical Group Limited ( (HK:2096) ) has issued an announcement.
Simcere Pharmaceutical Group Limited announced that its anti-tumor drug candidate, SIM0609, a CDH17 Antibody-Drug Conjugate, has received Clinical Trial Approval from China’s National Medical Products Administration. This approval allows the commencement of clinical trials for advanced solid tumors, potentially enhancing Simcere’s position in the oncology market and offering new treatment options for gastrointestinal carcinomas.
More about Simcere Pharmaceutical Group Limited
Simcere Pharmaceutical Group Limited is an innovation and R&D-driven pharmaceutical company focusing on neuroscience, anti-oncology, autoimmune, and anti-infection therapeutic areas. The company has established a ‘State Key Laboratory of Neurology and Oncology Drug Development’ and aims to address significant clinical needs through its strategic partnerships and in-house R&D efforts.
Average Trading Volume: 24,946,085
Technical Sentiment Signal: Buy
Current Market Cap: HK$35.24B
For a thorough assessment of 2096 stock, go to TipRanks’ Stock Analysis page.